바로가기메뉴

본문 바로가기 주메뉴 바로가기

ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

혈중 CA 125 수치가 지속적으로 상승되었던 기관지확장증 1예

A Case of Bronchiectasis with Elevated Serum CA 125 Level

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2009, v.66 no.6, pp.467-470
신봉철 (동아대학교)
구태형 (동아대학교)
김상옥 (동아대학교)
형건덕 (동아대학교)
엄수정 (동아대학교)
이수걸 (동아대학교)
손춘희 (동아대학교)
김기남 (동아대학교)
이기남 (동아대학교)
노미숙 (동아대학교)
최필조 (동아대학교)
  • 다운로드 수
  • 조회수

Abstract

Serum CA 125 is the most useful marker for monitoring patients with epithelial ovarian cancer. However, it can be elevated above normal level in a variety of conditions other than ovarian cancer such as endometriosis, pelvic inflammation disease, and other malignant or nonmalignant disorders, including pulmonary diseases. Recently, we experienced a case of bronchiectasis in which the serum CA 125 level was elevated, changing with the patient’s condition. There was no evidence of underlying malignant disease on positron emission tomography or on gynecologic examination, including transvaginal ultrasonography. During follow-up for 14 months, we could not find any clue of malignant disease that could have been the cause of the elevated levels of serum CA 125. Elevated serum CA 125 level should be interpreted carefully according to the patient’s clinical condition. In addition, our case suggests that CA 125 may be used as a surrogate marker for acute inflammatory status for chronic pulmonary diseases.

keywords
CA 125 antigen, Bronchiectasis, Benign

참고문헌

1.

Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1998;13:179-87.

2.

Topalak O, Saygili U, Soyturk M, Karaca N, Batur Y, Uslu T, et al. Serum, pleural effusion, and ascites CA- 125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 2002;85:108-13.

3.

Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 2000;75:264-5.

4.

Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003;10:150-4.

5.

Marechal F, Berthiot G, Deltour G. Serum levels of CA-50, CA-19.9, CA-125, CA-15.3, enolase and carcinoembryonic antigen in non neoplastic diseases of the lung. Anticancer Res 1988;8:677-80.

6.

Sevinc A, Camci C, Turk HM, Buyukberber S. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology 2003;65:1-6.

7.

Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;82:1535-8.

8.

Bischof P. What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol 1993;49:93-8.

9.

Ozsahin SL, Turgut B, Nur N, Dogan OT, Erselcan T, Berk S. Validity of the CA125 level in the differential diagnosis of pulmonary tuberculosis. Jpn J Infect Dis 2008;61:68-9.

10.

Kodama T, Satoh H, Ishikawa H, Ohtsuka M. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal 2007;21:103-6.

11.

Yilmaz A, Ece F, Bayramgürler B, Akkaya E, Baran R. The value of CA 125 in the evaluation of tuberculosis activity. Respir Med 2001;95:666-9.

Tuberculosis & Respiratory Diseases